Related Experiment Video
Updated: Jan 31, 2026

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
Published on: October 7, 2017
Bronchopulmonary Dysplasia: An Update of Current Pharmacologic Therapies and New Approaches
Zoe Michael1,2, Fotios Spyropoulos1,2,3, Sailaja Ghanta1,2
1Department of Pediatric Newborn Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Insights
Bronchopulmonary dysplasia (BPD) affects extremely preterm infants, with limited impact from new interventions. This review examines current and future pharmacologic treatments for BPD.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Pharmacology
Background:
- Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease in extremely preterm infants.
- Despite advances in neonatal care improving survival, BPD incidence remains high in extremely low birth weight (ELBW) infants.
- The complex etiology of BPD necessitates multifaceted prevention and treatment strategies.
Purpose of the Study:
- To review the current evidence for pharmacotherapy in the management of BPD.
- To discuss novel and emerging pharmacologic interventions for BPD.
- To highlight areas for future research in BPD pharmacotherapy.
Main Methods:
- Systematic review of existing literature on pharmacologic treatments for BPD.
- Analysis of clinical trial data and observational studies.
- Evaluation of preclinical research for novel therapeutic targets.
Main Results:
- Current pharmacotherapies show limited efficacy in preventing or treating BPD.
- Several agents are under investigation, including corticosteroids, diuretics, and bronchodilators.
- Emerging therapies target inflammation, lung repair, and vascular development.
Conclusions:
- Pharmacotherapy plays a role in managing BPD symptoms and complications.
- Further research is crucial to identify effective and safe pharmacologic treatments for BPD.
- A combination of interventions, including pharmacotherapy, is likely necessary for optimal BPD management.
Abstract:
Bronchopulmonary dysplasia (BPD) remains the most prevalent long-term morbidity of surviving extremely preterm infants and is associated with significant health care utilization in infancy and beyond. Recent advances in neonatal care have resulted in improved survival of extremely low birth weight (ELBW) infants; however, the incidence of BPD has not been substantially impacted by novel interventions in this vulnerable population. The multifactorial cause of BPD requires a multi-pronged approach for prevention and treatment. New approaches in assisted ventilation, optimal nutrition, and pharmacologic interventions are currently being evaluated. The focus of this review is the current state of the evidence for pharmacotherapy in BPD. Promising future approaches in need of further study will also be reviewed.
Related Concept Videos
Gene Therapy
Electrical Current
Group Therapy
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Current Density
Eddy Currents
Other major applications of eddy currents appear in metal detectors and the braking systems of trains and roller...

